Federal Judge Allows Telehealth Abortion Services to Continue Amid FDA Review
A federal judge in Louisiana has ruled that telehealth abortion services can continue while the FDA reviews the safety of mifepristone, a drug used in abortions. The ruling comes amid a legal challenge from Louisiana, which argues that the Biden Administration's removal of the in-person appointment requirement undermines the Supreme Court decision that overturned Roe v. Wade. The FDA is the defendant in the case, and two mifepristone drugmakers have intervened to defend their medications. The judge's decision grants a temporary stay, allowing the FDA to complete its review and update the court in six months. 
